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Neuroendocrine tumours (NETs) are a heterogeneous
group with significant variation in morphological charac-
teristics and functional behaviour. This poses challenges
in terms of both biochemical and imaging assessment.
Somatostatin receptor (sst) overexpression is documen-
ted in several malignancies. The sst subtype 2 (sst2) is
overexpressed in NETs [1] and can be targeted for both
somatostatin receptor scintigraphy and therapy.
In-111-octreotide (Octreoscan), a gamma imaging sst
agent, binds with relatively high affinity to sst 2.This has
good overall sensitivity in the detection of NETs (80-100%)
[2]. However, sensitivity varies according to tumour type,
grade, and location (e.g. sensitivity 24% in insulinomas) [3].
PET agents such as Ga-68-DOTA-labelled somatostatin
analogues have been developed with higher receptor affi-
nity when compared to gamma-based agents. This leads to
improved target-to-background ratio and provides the
improved imaging characteristics inherent of PET tracers.
A 2012 meta-analysis demonstrated pooled sensitivity and
specificity in detecting NETs of 93% and 91%, respectively
[4] with higher detection rates compared to conventional
sst imaging [5].
Whilst other PET tracers such as F-18-DOPA have
shown utility and higher sensitivity than conventional sst
scintigraphy, their role is limited to problem solving at
present. F-18-FDG can, however, provide prognostic infor-
mation with patients showing uptake having a progression
free survival of 0% at 2 years compared with 75±10% in
those without uptake [6].
Peptide receptor radionuclide therapy (PRRT) utilises
primarily beta-emitting radioisotopes such as Lu-177 and
Y-90 linked to somatostatin analogues such as DOTA-
TATE and DOTATOC. Whilst phase 3 data comparing
PRRT with other therapies is awaited, treatment with Y-90
and Lu-177 PRRT has been shown to have response rates
of approximately 80% and to confer a survival advantage
over historical controls [7]. Unsurprisingly, extensive hepa-
tic involvement is an adverse factor for progression free
survival, whereas high tumour uptake in pre-therapy ima-
ging confers prolonged survival [8].
Due to the differences in beta particle energy and path
length, it has been postulated that Lu-177 PRRT would be
best suited to smaller tumour volumes compared with
Y-90 which emits a more energetic particle with longer
path length. Kunikowska and colleagues have now demon-
strated that overall survival is significantly higher in
patients treated with combination Y-90/Lu-177-DOTA-
TATE compared with Y-90-DOTATATE alone [9].
Research into the role of sst antagonists is relatively new.
Several studies have shown a significantly greater number
of binding sites for antagonists when compared to agonists
such as Lu-177-DOTATATE. Pilot studies have shown
1.7-10.6 times higher tumour dose with the antagonist Lu-
177-DOTA-JR11 when compared to Lu-177-DOTATATE
[10]. Encouraging results have also been obtained with the
use of radiosensitising chemotherapeutic agents adminis-
tered together with PRRT. A phase 2 study evaluating
capecitabine with Lu-177-octreotate demonstrated a
response rate of 94% with no significant increase in toxi-
city [11]. Further work is required, however, these
advances are likely to play a significant role in the future.
Published: 2 October 2015
References
1. Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5
expression in normal and neoplastic human tissues using receptor
autoradiography with subtype-selective ligands. Eur J Nucl Med 2001,
28:836-846.
2. Teunissen JJM, Kwekkeboom DJ, Valkema R, et al: Nuclear Medicine
techniques for the imaging and treatment of neuroendocrine tumours.
Endocrine-Related Cancer 2011, 18:s27-s51.
3. Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients:
efficacy on hypoglycaemia, relationships with octreoscan scintigraphyDepartment of Nuclear Medicine, Plymouth Hospitals NHS Trust, Plymouth,
Devon PL6 8DH, UK
Drake and Grüning Cancer Imaging 2015, 15(Suppl 1):O16
http://www.cancerimagingjournal.com/content/15/S1/O16
© 2015 Drake and Grüning This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and immunostaining with anti-sst2a and anti-sst5 antibodies. Eur J
Endocrinology 2005, 152:757-767.
4. Treglia G, Castaldi P, Rindi G, et al: Diagnostic performance of gallium-68
somatostatin receptor PET and PET CT in patients with thoracic and
gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Endocrine 2012, 42:80-87.
5. Gabriel M, Decristo C, Kendler D, et al: 68 Ga-DOTA-Tyr3-Octreotide PET in
neuroendocrine tumours: Comparison with Somatostatin receptor
scintigraphy and CT. J Nucl Med 2007, 48:508-518.
6. Garin E, Le Jeune F, Devillers A, et al: Predictive Value of 18F-FDG PET and
somatostatin receptor scintigraphy in patients with metastatic endocrine
tumours. J Nucl Med 2009, 50:858-864.
7. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the
radiolabelled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate:
toxicity, efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
8. Imhof A, Brunner P, Marincek N, et al: Response, survival and long -term
toxicity after therapy with the radio labelled somatostatin analogue[90Y-
DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011,
29:2416-2423.
9. Kunikowska J, Krolicka L, Hubalewska-Dydejczyk A, et al: Clinical results of
radionuclide therapy of neuroendocrine tumours with Y90-DOTATATE
and tandem Y90/Lu177-DOTATATE: which is better therapy option? Eur
J Nucl Med Mol Imaging 2011, 38:1788-1797.
10. Wild D, Fani M, Fischer R, et al: Comparison of somatostatin receptor
agonist and antagonis for peptide receptor radionuclide therapy: A pilot
study. J Nucl Med 2014, 55:1-5.
11. Claringbold PG, Brayshaw PA, Price RA, et al: Lu177-octreotate and
capecitabine therapy of progressive disseminated neuroendocrine
tumours. Eur J Nucl Med Mol Imaging 2011, 38:302-311.
doi:10.1186/1470-7330-15-S1-O16
Cite this article as: Drake and Grüning: Theranostics: radionuclide
imaging and therapy in neuroendocrine tumours. Cancer Imaging 2015
15(Suppl 1):O16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Drake and Grüning Cancer Imaging 2015, 15(Suppl 1):O16
http://www.cancerimagingjournal.com/content/15/S1/O16
Page 2 of 2
